Table 5 Practice dimension of the participants.
Practice | Never | Occasionally | Sometimes | Often | Always |
|---|---|---|---|---|---|
1. I will explain to patients the incidence and hazards of DVT before surgery. | 16(7.8%) | 6(2.9%) | 14(6.8%) | 50(24.4%) | 119(58%) |
2. I will recommend DVT prevention measures for postoperative patients. | 11(5.4%) | 2(1%) | 9(4.4%) | 45(22%) | 138(67.3%) |
3. I will provide education on DVT prevention for postoperative patients. | 10(4.9%) | 2(1%) | 13(6.3%) | 44(21.5%) | 136(66.3%) |
4. I will actively monitor whether postoperative patients adhere to DVT prevention measures. | 9(4.4%) | 3(1.5%) | 16(7.8%) | 55(26.8%) | 122(59.5%) |
5. I will regularly assess the risk of DVT in postoperative patients. | 9(4.4%) | 2(1%) | 18(8.8%) | 45(22%) | 131(63.9%) |
6. I will assess the risk of DVT in patients using thromboelastography, as well as coagulation and platelet function analysis. | 10(4.9%) | 22(10.7%) | 36(17.6%) | 47(22.9%) | 90(43.9%) |
7. For patients at high risk of DVT, I will take preventive measures before surgery. | 9(4.4%) | 3(1.5%) | 26(12.7%) | 46(22.4%) | 121(59%) |
8. I will choose different drug treatments for DVT based on the patient’s condition. | 13(6.3%) | 11(5.4%) | 22(10.7%) | 44(21.5%) | 115(56.1%) |
9. I will use D-dimer levels to guide the use of treatment drugs postoperatively. | 13(6.3%) | 8(3.9%) | 23(11.2%) | 49(23.9%) | 112(54.6%) |
10. After patients develop DVT and receive timely medication, I will use thromboelastography, as well as coagulation and platelet function tests, to assess the effects of the drugs. | 12(5.9%) | 19(9.3%) | 31(15.1%) | 49(23.9%) | 94(45.9%) |
